Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis

Despite limited efficacy of immunotherapy for advanced non-small-cell lung cancer (NSCLC) with driver mutations, whether neoadjuvant immunotherapy could be clinically valuable in those patients warrants further investigation. We utilized 40 oncogene-mutant NSCLC treated with induction immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chao, Chen, Hua-Fei, Yan, Shi, Wu, Lin, Yan, Li-Xu, Yan, Xiao-Long, Yue, Dong-Sheng, Xu, Chun-Wei, Zheng, Min, Li, Ji-Sheng, Liu, Si-Yang, Yang, Ling-Ling, Jiang, Ben-Yuan, Ou, Qiu-Xiang, Qiu, Zhen-Bin, Shao, Yang, Wu, Yi-Long, Zhong, Wen-Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485257/
https://www.ncbi.nlm.nih.gov/pubmed/36123526
http://dx.doi.org/10.1038/s41698-022-00301-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485257/
https://www.ncbi.nlm.nih.gov/pubmed/36123526
http://dx.doi.org/10.1038/s41698-022-00301-8

Ejemplares similares